MediWound Ltd.

MediWound Ltd. is a risky bet given it's low Altman Z-score. Companies with a low Altman Z-score have a higher chance of going bankrupt within the next 2 years. The stock has a good momentum. MediWound Ltd. is not a good value stock. MediWound Ltd. is not a good growth stock. MediWound Ltd. is a mediocre stock to choose.
Log in to see more information.
MediWound Ltd. is a biopharmaceutical company, which engages in the development, manufacture and com...
MDWD Fundamental Data by TradingView

News

MediWound to Present at the H.C. Wainwright 26th Annual Global Investment Conference
MediWound to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Globe Newswire YAVNE, Israel, Sept. 03, 2024 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), the global leader in next-generation enzymatic therapeutics for tissue repair, today announced that Ofer Gonen...\n more…

MediWound files to sell 1.45M ordinary shares for holders
MediWound files to sell 1.45M ordinary shares for holders

SeekingAlpha.com: All News MediWound (MDWD) filed a prospectus related to a new financial offering, signaling potential growth and investment opportunities in the company.\n more…

MediWound files to sell 1.45M ordinary shares for holders
MediWound files to sell 1.45M ordinary shares for holders

The Fly See the rest of the story here.\n\nthefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...\n more…

Critical Comparison: MediWound (NASDAQ:MDWD) versus Jinhua Marine Biological (OTCMKTS:JNMB)
Critical Comparison: MediWound (NASDAQ:MDWD) versus Jinhua Marine Biological (OTCMKTS:JNMB)

Ticker Report Jinhua Marine Biological (OTCMKTS:JNMB - Get Free Report) and MediWound (NASDAQ:MDWD - Get Free Report) are both medical companies, but which is the better investment? We will contrast the two...\n more…

Mediwound Poised for Growth: Buy Rating Backed by NexoBrid Expansion and EscharEx Market Potential
Mediwound Poised for Growth: Buy Rating Backed by NexoBrid Expansion and EscharEx Market Potential

TipRanks Financial Blog Mediwound (MDWD - Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Michael Okunewitch fro...\n more…

Brokers Set Expectations for MediWound Ltd.'s Q3 2024 Earnings (NASDAQ:MDWD)
Brokers Set Expectations for MediWound Ltd.'s Q3 2024 Earnings (NASDAQ:MDWD)

Ticker Report MediWound Ltd. (NASDAQ:MDWD - Free Report) - Analysts at HC Wainwright raised their Q3 2024 earnings estimates for MediWound in a research report issued on Thursday, August 15th. HC Wainwright...\n more…